

antiangiogenic agent bevacizumab, in newly diagnosed patients with STS with the hope of improving EFS in these poor prognosis patients. With the ITCC the EpSSG group has now developed a strategy for the introduction of novel agents in RMS and is expecting to open an investigator led, limited centre, randomized, phase II study in 2011 to define the optimal chemotherapy backbone in relapsed/refractory patients to which novel agents can subsequently be added. In addition, following a series of workshops, the EpSSG and ITCC have together defined a model paediatric investigation plan to guide the investigation of novel agents in children with RMS. The intention is that a clear research strategy and engagement with pharma at an early stage of drug development may help to realise some of the key challenges in improving the management of RMS.

102

INVITED

Recent Advancements for High Risk Neuroblastoma (HRN) in Europe Through the SIOP Europe Neuroblastoma Group (SIOPEN)

R. Ladenstein¹. ¹ St. Anna's Children's Hospital and Children's Cancer Research Institute, Paediatric Haematology Oncology, Vienna, Austria

Neuroblastoma, a cancer of the sympathetic nervous system, is a heterogeneous disease with over 50% of patients having a high risk phenotype characterised by wide-spread dissemination or unfavourable biology in localised disease. Their long term survival is poor even if intensive multimodal treatments are used.

The HR-NBL1/SIOPEN trial randomised 2 myeloablative (MAT) regimens for this setting: BuMel (oral busulfan till 2006, 4×150 mg/m² in 4 equal doses, or after 2006 intravenous use according to body weight and melphalan 140 mg/m²/day) and CEM (carboplatin ctn. infusion (4×AUC 4.1 mg/ml.min/day), etoposide ctn. infusion (4×338 mg/m²/day or 4×200 mg/m²/day*), melphalan (3×70 mg/m²/day or 3×60 mg/m²/day*). *reduced if GFR <100 ml/min/1.73m²). A minimum of 3×10⁶ CD34/kgBW PBSC were requested. VOD prophylaxis included ursadiol, but not prophylactic defibrotide. At randomisation closure, 1577 high risk neuroblastoma patients (944 males) had been included since 2002; with INSS stage 4 disease (1369 pts) >1 year, infants (65 pts) and stage 2&3 (143 pts) of any age with MYCN amplification. Response eligibility criteria prior to randomisation after Rapid COJEC Induction (J Clin Oncol, 2010) ± 2 courses of TVD (Cancer, 2003) included complete bone marrow remission and ≤3, but improved, mIBG positive spots. Local control included surgery and radiotherapy of 21 Gy. A total of 598 patients were randomised (296 BuMel, 302 CEM). The median age at randomisation was 3 years (1–17.2) with a median follow up of 3 years. A significant difference in EFS in favour of BuMel (3-years EFS 49% vs. 33%) was observed as well as for overall survival (3-years OS 60% vs. 48%, p=0.004). This difference was mainly related to the relapse and progression incidence, which was significantly (p<0.001) lower with BuMel (48% vs. 60%). Also the acute MAT toxicity profile favours the BuMel regimen in spite of a total VOD incidence of 18% (grade 3:5%). Thus BuMel was demonstrated to be superior to CEM and hence is recommended as standard treatment.

In addition, the HR-NBL1 trial established the prognostic value of semi-quantitative I-123 mIBG scintigraphy at diagnosis in high risk neuroblastoma. Patterns of skeletal I-123 mIBG uptake were assigned numerical scores (Mscore). SIOPEN scoring of I-123 mIBG imaging predicts response to induction chemotherapy and outcome at diagnosis in children with HRN and will help be a toll for risk based stratification.

103

INVITED

Research and Therapeutic Strategy of the European Intergroup for Children Non Hodgkin Lymphomas (EICNHL)

C. Patte¹, D. Williams², A. Rosolen³, L. Brugieres⁴, B. Kazanowska⁵, A. Beishuizen⁶, A. Uytendaele⁷, K. Mellgren⁸, W. Woessmann⁹, A. Reiter⁹. ¹Institut Gustave Roussy, Paediatric, Villejuif, France; ²Addenbrookes Hospital, Paediatric, Cambridge, United Kingdom;

³Università di Padova, Paediatric Clinica di Oncoematologia Pediatrica, Padova, Italy; ⁴Institut Gustave Roussy, Pediatric, Villejuif, France;

⁵Clinic of Pediatric Oncology, Paediatric, Wroclaw, Poland; ⁶Kinderarts Oncoloog/Hematoloog, Erasmus MC – Sophia Kinderziekenhuis, Rotterdam, Netherlands Antilles; ⁷University Hospital, Paediatric, Leuven, Belgium; ⁸Ungdomssjukhus, Paediatric, Göteborg, Sweden; ⁹University Children's Hospital, Paediatric, Giessen, Germany

In 1996, the EICNHL was created by several paediatric hemato-oncologists to meet, exchange data and design common studies on NHL.

The first studies were for ALL (~10% of NHL in children). Based on a retrospective analysis of pooled data of several groups, prognostic factors were identified allowing designing the randomised ALL99 study. This study demonstrated the possibility to do a large European study, including

Japan (but before the European Directive). Besides conclusions on therapy, it allowed collecting clinical, pathological and biological data on more than 350 patients (pts). In parallel, was run a prospective study on relapses. The next randomised study will address the question of vinblastine in 1st line after stratification on biological data (MDD and ALK antibody title) with parallel biological studies, especially on antitumour immunity. EICNHL in collaboration with ITCC and COG is planning to study new drugs such as anti ALK or SGN35.

Lymphoblastic NHL (~25% NHL) was subject of the 2nd EICNHL study which randomised dexamethasone vs prednisone in induction of the nonB-BFM 90 scheme. Unfortunately, the study had to stop because of toxic death rate higher than expected. However, it registered more than 300 pts treated homogeneously which should allow drawing conclusions on the disease.

For the B-cell NHL (~60%), the focus was first on PMBL which had poorer results with an attempt to develop a common strategy using rituximab. Then the other B-NHL (Burkitt and DLBCL) were considered: the 2 strategies developed in Europe since 1981 by the French LMB and the German BFM groups had allowed reaching >85% cure rates. Although using the same drugs in a same general strategy, the risk stratification, therapy and weight of treatment show dissimilarities. A study pooling data of 2 more recent studies of each group showed similar results, overall and by stage. This encouraged planning a common study to question the benefit of rituximab in advanced stage pts. Finally it will a LMB based protocol, with or without rituximab, considered as an investigational drug in children. This study will also be made with COG and maybe Hong Kong and Japan. The BFM group piloted an upfront window with 1 injection of rituximab 5 days before start of chemotherapy showing some response and will see how to go further with this information.

Conclusion: Despite regulatory processes being heavier after the EU directive, European studies for NHL must be encouraged because of the rarity of the disease.

104

INVITED

Relapsed Acute Lymphoblastic Leukemia

M. Schrappe¹. ¹University Kinderklinik, Kiel, Germany

Childhood ALL is characterized by a wide range of clinical and biological features at time of diagnosis. Age, leukemic cell count, CNS involvement, immunophenotype, and genetic subtype may be relevant for a first assessment of the immediate disease-related risk for the patient, and for determining the treatment strategy. Systematic evaluation of these features in the setting of cooperative clinical trials, however, has revealed the limitations to predict the risk of relapse. Therefore, the detailed analysis of early treatment response since the 1980's has revealed the large heterogeneity of in vivo treatment sensitivity, even within well-defined ALL subgroups. While estimates of relapse probabilities have improved over the past 20 years, individual parameters to predict relapse reliably are still missing. Thus, the vast majority of relapses occurs among patients with so-called intermediate risk features while the relatively highest proportion does occur among the rare high risk subsets such as children with translocation t(4;11) or t(9;22). Similar to first diagnosis, predictors of survival after 1st relapse relate to genetic and immunophenotypic subgroup, and clinical parameters such as involvement of extramedullary sites (Tallen G et al, J Clin Oncol 2010; Gaynon PS et al, Cancer 1998). Time of relapse from first diagnosis and response to second line therapy are strong prognostic parameters: Any relapse occurring during first line therapy is particularly unfavorable as this illustrates aggressive disease refractory to the wide range of antileukemic agents used in most contemporary protocols. No response to retrieval therapy is a strong adverse factor as is the slow response to 2nd line therapy measured by assessment of minimal residual disease (MRD) (Eckert C. et al, LANCET 2001). Recently, clonal heterogeneity in relapsed ALL when compared to initial presentation has been documented (Eckert C et al, LEUKEMIA 2011). Intensified chemotherapy can rescue a large proportion of relapsed patients. (Henze G et al 1994; von Stackelberg et al Eur J Cancer 2011). Relapsed ALL offers certainly also a window for clinical evaluation of new agents not used in standard frontline therapy. Recently it was shown in a U.K. study that mitoxantrone a drug which is frequently used in AML therapy, has a profound efficacy in relapsed ALL (Parker C et al, LANCET 2010). In some subsets, the introduction of allogeneic hematopoietic stem cell transplantation has further improved outcome (Borgmann A et al, Blood 2003). Recently, novel antibody constructs demonstrated high efficacy in relapsed ALL (Handgretinger R et al, Leukemia 2011). Cooperative clinical trials have contributed significantly to improve survival after first and subsequent disease recurrence. European approaches to combine diagnostic and research expertise and to develop innovative treatment in this difficult patient population are underway and will be described.